Melanie Cree
Concepts (426)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Ovary Syndrome | 28 | 2026 | 191 | 12.300 |
Why?
| | Insulin Resistance | 64 | 2026 | 1247 | 10.130 |
Why?
| | Diabetes Mellitus, Type 2 | 34 | 2026 | 2623 | 3.910 |
Why?
| | Mitochondria, Muscle | 12 | 2026 | 125 | 3.480 |
Why?
| | Obesity | 32 | 2026 | 3131 | 3.440 |
Why?
| | Blood Glucose | 40 | 2026 | 2360 | 3.120 |
Why?
| | Pediatric Obesity | 13 | 2026 | 635 | 2.880 |
Why?
| | Glucose Intolerance | 11 | 2021 | 142 | 2.680 |
Why?
| | Muscle, Skeletal | 33 | 2026 | 1818 | 2.590 |
Why?
| | Glucose Clamp Technique | 16 | 2023 | 199 | 2.440 |
Why?
| | Testosterone | 8 | 2026 | 419 | 2.160 |
Why?
| | Metformin | 10 | 2021 | 328 | 2.150 |
Why?
| | Adolescent | 87 | 2026 | 22557 | 2.140 |
Why?
| | Glucose Tolerance Test | 21 | 2025 | 360 | 2.130 |
Why?
| | Insulin | 29 | 2026 | 2525 | 2.120 |
Why?
| | Fatty Liver | 7 | 2026 | 252 | 2.090 |
Why?
| | Liver | 13 | 2026 | 1864 | 2.010 |
Why?
| | Fasting | 7 | 2024 | 280 | 1.910 |
Why?
| | Triglycerides | 10 | 2026 | 527 | 1.840 |
Why?
| | Hyperandrogenism | 3 | 2024 | 25 | 1.770 |
Why?
| | Fatty Acids, Nonesterified | 7 | 2018 | 154 | 1.510 |
Why?
| | Diabetes Mellitus, Type 1 | 17 | 2024 | 3930 | 1.440 |
Why?
| | Lipid Metabolism | 7 | 2026 | 533 | 1.420 |
Why?
| | Metabolic Syndrome | 3 | 2020 | 364 | 1.420 |
Why?
| | Body Mass Index | 15 | 2026 | 2458 | 1.410 |
Why?
| | Female | 110 | 2026 | 79499 | 1.360 |
Why?
| | Burns | 9 | 2010 | 365 | 1.280 |
Why?
| | Adipose Tissue | 7 | 2026 | 642 | 1.270 |
Why?
| | Lipolysis | 4 | 2019 | 44 | 1.270 |
Why?
| | Hyperinsulinism | 4 | 2019 | 115 | 1.230 |
Why?
| | Child | 53 | 2026 | 22693 | 1.170 |
Why?
| | Circadian Rhythm | 7 | 2025 | 515 | 1.150 |
Why?
| | Young Adult | 38 | 2026 | 14330 | 1.150 |
Why?
| | Humans | 132 | 2026 | 146342 | 1.100 |
Why?
| | Exercise | 15 | 2026 | 2213 | 1.100 |
Why?
| | Magnetic Resonance Spectroscopy | 9 | 2024 | 627 | 1.070 |
Why?
| | Glycerol | 6 | 2023 | 90 | 1.060 |
Why?
| | Cross-Sectional Studies | 22 | 2024 | 5899 | 1.050 |
Why?
| | Oxidative Phosphorylation | 4 | 2019 | 212 | 1.040 |
Why?
| | Body Composition | 8 | 2026 | 689 | 0.970 |
Why?
| | Glucose | 10 | 2023 | 1053 | 0.930 |
Why?
| | Hypoglycemic Agents | 9 | 2019 | 1412 | 0.900 |
Why?
| | Case-Control Studies | 16 | 2025 | 3647 | 0.890 |
Why?
| | Cardiovascular Diseases | 7 | 2025 | 2219 | 0.890 |
Why?
| | Insulin-Secreting Cells | 6 | 2020 | 393 | 0.870 |
Why?
| | Male | 82 | 2026 | 73396 | 0.850 |
Why?
| | Androgens | 2 | 2022 | 179 | 0.770 |
Why?
| | Prediabetic State | 4 | 2021 | 250 | 0.760 |
Why?
| | Sleep | 6 | 2026 | 896 | 0.750 |
Why?
| | Sleep Initiation and Maintenance Disorders | 2 | 2020 | 198 | 0.730 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2021 | 265 | 0.720 |
Why?
| | Gastrointestinal Microbiome | 2 | 2021 | 769 | 0.720 |
Why?
| | Hyperglycemia | 4 | 2021 | 384 | 0.710 |
Why?
| | Adult | 48 | 2026 | 41087 | 0.700 |
Why?
| | Transition to Adult Care | 1 | 2024 | 111 | 0.700 |
Why?
| | Adenosine Diphosphate | 2 | 2021 | 75 | 0.670 |
Why?
| | Adolescent Medicine | 1 | 2020 | 26 | 0.630 |
Why?
| | Klinefelter Syndrome | 1 | 2021 | 68 | 0.630 |
Why?
| | Desogestrel | 1 | 2020 | 46 | 0.630 |
Why?
| | Absorptiometry, Photon | 7 | 2026 | 278 | 0.610 |
Why?
| | Lipogenesis | 2 | 2019 | 62 | 0.610 |
Why?
| | Obesity, Morbid | 1 | 2024 | 287 | 0.610 |
Why?
| | Overweight | 6 | 2025 | 614 | 0.610 |
Why?
| | Isotopes | 1 | 2019 | 33 | 0.600 |
Why?
| | Inservice Training | 1 | 2020 | 115 | 0.590 |
Why?
| | Endocrinology | 1 | 2020 | 77 | 0.590 |
Why?
| | Gluconeogenesis | 1 | 2019 | 81 | 0.560 |
Why?
| | Adiposity | 5 | 2025 | 533 | 0.560 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2019 | 55 | 0.560 |
Why?
| | Energy Metabolism | 3 | 2024 | 930 | 0.550 |
Why?
| | Obesity, Abdominal | 1 | 2018 | 48 | 0.550 |
Why?
| | Mentors | 1 | 2020 | 217 | 0.530 |
Why?
| | Gynecology | 1 | 2020 | 185 | 0.530 |
Why?
| | C-Peptide | 6 | 2026 | 191 | 0.530 |
Why?
| | Interprofessional Relations | 1 | 2020 | 275 | 0.520 |
Why?
| | Biodiversity | 1 | 2020 | 314 | 0.510 |
Why?
| | Mentoring | 1 | 2020 | 166 | 0.510 |
Why?
| | Depressive Disorder | 1 | 2020 | 361 | 0.500 |
Why?
| | Fenofibrate | 2 | 2007 | 28 | 0.500 |
Why?
| | Fatty Acids | 2 | 2019 | 460 | 0.500 |
Why?
| | Amino Acids | 3 | 2019 | 515 | 0.490 |
Why?
| | Lipoproteins, HDL | 1 | 2017 | 104 | 0.490 |
Why?
| | Hypolipidemic Agents | 2 | 2007 | 89 | 0.480 |
Why?
| | Oxygen Consumption | 9 | 2024 | 721 | 0.480 |
Why?
| | Diabetic Nephropathies | 4 | 2026 | 320 | 0.460 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2025 | 88 | 0.430 |
Why?
| | Muscle Proteins | 7 | 2017 | 242 | 0.430 |
Why?
| | Bacteria | 1 | 2020 | 766 | 0.420 |
Why?
| | Severity of Illness Index | 4 | 2025 | 2921 | 0.420 |
Why?
| | Mitochondria | 5 | 2024 | 997 | 0.410 |
Why?
| | Lipoproteins | 1 | 2015 | 165 | 0.410 |
Why?
| | Gastrectomy | 2 | 2026 | 164 | 0.400 |
Why?
| | Magnetic Resonance Imaging | 8 | 2026 | 3926 | 0.400 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 1101 | 0.400 |
Why?
| | Prognosis | 5 | 2020 | 4351 | 0.400 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2025 | 300 | 0.400 |
Why?
| | Aging | 3 | 2019 | 1996 | 0.390 |
Why?
| | B-Lymphocytes | 1 | 2019 | 887 | 0.390 |
Why?
| | PPAR alpha | 3 | 2007 | 56 | 0.380 |
Why?
| | Cohort Studies | 9 | 2021 | 6077 | 0.380 |
Why?
| | Weight Loss | 4 | 2026 | 858 | 0.380 |
Why?
| | Decision Making | 1 | 2020 | 993 | 0.370 |
Why?
| | Cardiorespiratory Fitness | 3 | 2024 | 73 | 0.370 |
Why?
| | Sleep Deprivation | 2 | 2025 | 207 | 0.370 |
Why?
| | Oxygen | 1 | 2018 | 997 | 0.370 |
Why?
| | Bed Rest | 2 | 2009 | 14 | 0.370 |
Why?
| | Risk Factors | 12 | 2025 | 10921 | 0.360 |
Why?
| | Follow-Up Studies | 6 | 2020 | 5439 | 0.360 |
Why?
| | Calorimetry, Indirect | 2 | 2024 | 72 | 0.350 |
Why?
| | Insulin Glargine | 3 | 2019 | 88 | 0.340 |
Why?
| | Actigraphy | 5 | 2026 | 148 | 0.330 |
Why?
| | Puberty | 3 | 2024 | 141 | 0.330 |
Why?
| | Cystic Fibrosis | 1 | 2020 | 1164 | 0.310 |
Why?
| | Hirsutism | 2 | 2021 | 12 | 0.310 |
Why?
| | Middle Aged | 19 | 2026 | 36619 | 0.310 |
Why?
| | Cushing Syndrome | 1 | 2009 | 10 | 0.310 |
Why?
| | Gastroplasty | 2 | 2021 | 31 | 0.300 |
Why?
| | Algorithms | 2 | 2021 | 1849 | 0.290 |
Why?
| | Estradiol | 3 | 2022 | 517 | 0.280 |
Why?
| | Pleural Neoplasms | 1 | 2009 | 31 | 0.280 |
Why?
| | Prospective Studies | 7 | 2020 | 8123 | 0.280 |
Why?
| | Mesothelioma | 1 | 2009 | 50 | 0.270 |
Why?
| | Melatonin | 4 | 2025 | 165 | 0.270 |
Why?
| | Retrospective Studies | 8 | 2024 | 17438 | 0.260 |
Why?
| | Protein Kinase C | 1 | 2008 | 250 | 0.250 |
Why?
| | Sex Characteristics | 3 | 2025 | 801 | 0.240 |
Why?
| | Exercise Tolerance | 4 | 2017 | 289 | 0.240 |
Why?
| | Diabetes, Gestational | 2 | 2025 | 307 | 0.240 |
Why?
| | Diabetic Cardiomyopathies | 2 | 2016 | 34 | 0.230 |
Why?
| | Janus Kinases | 1 | 2026 | 21 | 0.230 |
Why?
| | STAT Transcription Factors | 1 | 2026 | 25 | 0.230 |
Why?
| | Autoimmunity | 1 | 2012 | 925 | 0.230 |
Why?
| | Apolipoproteins B | 1 | 2025 | 48 | 0.220 |
Why?
| | Saliva | 3 | 2025 | 256 | 0.220 |
Why?
| | Abdominal Fat | 1 | 2025 | 51 | 0.220 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2026 | 141 | 0.220 |
Why?
| | Metabolic Diseases | 1 | 2026 | 114 | 0.210 |
Why?
| | Reproducibility of Results | 8 | 2025 | 3416 | 0.210 |
Why?
| | Biological Clocks | 1 | 2025 | 48 | 0.210 |
Why?
| | Carotid Intima-Media Thickness | 3 | 2025 | 75 | 0.210 |
Why?
| | Carnitine | 3 | 2019 | 91 | 0.210 |
Why?
| | Adiponectin | 2 | 2016 | 243 | 0.210 |
Why?
| | Time Factors | 7 | 2026 | 7109 | 0.210 |
Why?
| | Lipoproteins, VLDL | 1 | 2024 | 21 | 0.210 |
Why?
| | Alanine Transaminase | 1 | 2024 | 151 | 0.200 |
Why?
| | Terminology as Topic | 1 | 2026 | 253 | 0.200 |
Why?
| | Basal Metabolism | 1 | 2024 | 58 | 0.200 |
Why?
| | Adenosine Triphosphate | 2 | 2021 | 494 | 0.200 |
Why?
| | Polysomnography | 1 | 2025 | 239 | 0.200 |
Why?
| | Muscle Contraction | 3 | 2014 | 438 | 0.200 |
Why?
| | Age Factors | 3 | 2020 | 3347 | 0.200 |
Why?
| | Dyslipidemias | 1 | 2025 | 184 | 0.200 |
Why?
| | Leg | 5 | 2021 | 246 | 0.200 |
Why?
| | Aged | 12 | 2020 | 26432 | 0.200 |
Why?
| | Endocrine System Diseases | 1 | 2023 | 35 | 0.190 |
Why?
| | Continuity of Patient Care | 1 | 2006 | 298 | 0.190 |
Why?
| | Ventricular Remodeling | 1 | 2025 | 283 | 0.190 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 215 | 0.190 |
Why?
| | Vascular Stiffness | 2 | 2019 | 488 | 0.190 |
Why?
| | Muscle Strength | 2 | 2017 | 340 | 0.190 |
Why?
| | Colorado | 5 | 2020 | 4595 | 0.180 |
Why?
| | Carbon Isotopes | 4 | 2019 | 143 | 0.180 |
Why?
| | Lipids | 4 | 2017 | 714 | 0.180 |
Why?
| | Bariatric Surgery | 1 | 2026 | 250 | 0.180 |
Why?
| | Sex Factors | 3 | 2017 | 2107 | 0.170 |
Why?
| | Heart | 1 | 2025 | 626 | 0.170 |
Why?
| | Double-Blind Method | 3 | 2019 | 2070 | 0.170 |
Why?
| | Biomarkers | 6 | 2019 | 4340 | 0.170 |
Why?
| | Phosphocreatine | 1 | 2021 | 44 | 0.170 |
Why?
| | Atherosclerosis | 1 | 2025 | 410 | 0.170 |
Why?
| | Child, Preschool | 9 | 2022 | 11913 | 0.170 |
Why?
| | Tandem Mass Spectrometry | 1 | 2024 | 576 | 0.170 |
Why?
| | Incidence | 3 | 2021 | 2936 | 0.170 |
Why?
| | Glutathione | 1 | 2023 | 369 | 0.170 |
Why?
| | Hospitalization | 2 | 2016 | 2475 | 0.170 |
Why?
| | Alopecia | 1 | 2021 | 33 | 0.170 |
Why?
| | Bacteroidetes | 1 | 2021 | 20 | 0.170 |
Why?
| | Body Weight | 2 | 2019 | 968 | 0.160 |
Why?
| | Sleep Wake Disorders | 2 | 2019 | 314 | 0.160 |
Why?
| | Transgender Persons | 1 | 2024 | 213 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2240 | 0.160 |
Why?
| | Contraceptive Devices, Female | 1 | 2020 | 14 | 0.160 |
Why?
| | Sex Chromosome Disorders of Sex Development | 1 | 2020 | 16 | 0.160 |
Why?
| | United States | 4 | 2026 | 16136 | 0.160 |
Why?
| | Drug Implants | 1 | 2020 | 83 | 0.160 |
Why?
| | Ovarian Reserve | 1 | 2020 | 19 | 0.160 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2020 | 40 | 0.150 |
Why?
| | Protein Biosynthesis | 2 | 2017 | 449 | 0.150 |
Why?
| | Prednisolone | 1 | 2019 | 65 | 0.150 |
Why?
| | Glucose Metabolism Disorders | 1 | 2019 | 9 | 0.150 |
Why?
| | Arginine | 2 | 2019 | 264 | 0.150 |
Why?
| | Sitagliptin Phosphate | 1 | 2019 | 31 | 0.150 |
Why?
| | Liraglutide | 1 | 2019 | 32 | 0.150 |
Why?
| | Linear Models | 3 | 2014 | 857 | 0.150 |
Why?
| | Amino Acids, Essential | 2 | 2009 | 13 | 0.150 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2019 | 145 | 0.140 |
Why?
| | Uromodulin | 1 | 2019 | 22 | 0.140 |
Why?
| | Virilism | 1 | 2019 | 6 | 0.140 |
Why?
| | Device Removal | 1 | 2020 | 149 | 0.140 |
Why?
| | Menstruation Disturbances | 1 | 2019 | 13 | 0.140 |
Why?
| | Waist Circumference | 1 | 2019 | 142 | 0.140 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2019 | 51 | 0.140 |
Why?
| | Physicians, Women | 1 | 2020 | 92 | 0.140 |
Why?
| | Aorta | 2 | 2019 | 440 | 0.140 |
Why?
| | Diastole | 1 | 2019 | 147 | 0.140 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 46 | 0.140 |
Why?
| | Contraceptives, Oral | 1 | 2019 | 37 | 0.140 |
Why?
| | Withholding Treatment | 1 | 2019 | 77 | 0.140 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 507 | 0.140 |
Why?
| | Spironolactone | 1 | 2019 | 40 | 0.140 |
Why?
| | Respiratory Function Tests | 1 | 2020 | 543 | 0.140 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 2113 | 0.140 |
Why?
| | Cardiotonic Agents | 1 | 2018 | 96 | 0.140 |
Why?
| | Deuterium | 3 | 2015 | 101 | 0.130 |
Why?
| | Minority Groups | 1 | 2020 | 286 | 0.130 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 522 | 0.130 |
Why?
| | Career Choice | 1 | 2020 | 237 | 0.130 |
Why?
| | Cell Respiration | 1 | 2018 | 104 | 0.130 |
Why?
| | Peer Group | 1 | 2020 | 251 | 0.130 |
Why?
| | Wakefulness | 1 | 2019 | 170 | 0.130 |
Why?
| | Intra-Abdominal Fat | 1 | 2018 | 104 | 0.130 |
Why?
| | Spasms, Infantile | 1 | 2019 | 138 | 0.130 |
Why?
| | Alberta | 2 | 2009 | 25 | 0.130 |
Why?
| | Universities | 1 | 2020 | 451 | 0.130 |
Why?
| | Feces | 1 | 2021 | 496 | 0.130 |
Why?
| | Social Media | 1 | 2020 | 159 | 0.130 |
Why?
| | Phosphorus Isotopes | 1 | 2017 | 8 | 0.130 |
Why?
| | Erythrocytes | 1 | 2023 | 750 | 0.130 |
Why?
| | Blood Vessels | 1 | 2018 | 164 | 0.130 |
Why?
| | Hindlimb | 1 | 2017 | 128 | 0.130 |
Why?
| | Child Behavior | 1 | 2019 | 234 | 0.120 |
Why?
| | Kidney | 4 | 2021 | 1498 | 0.120 |
Why?
| | Affect | 1 | 2019 | 318 | 0.120 |
Why?
| | Human Development | 1 | 2016 | 22 | 0.120 |
Why?
| | Occupational Exposure | 1 | 2020 | 356 | 0.120 |
Why?
| | Placental Insufficiency | 1 | 2017 | 126 | 0.120 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 561 | 0.120 |
Why?
| | Bone Density | 1 | 2020 | 494 | 0.120 |
Why?
| | Regional Blood Flow | 2 | 2016 | 507 | 0.120 |
Why?
| | Parenting | 1 | 2020 | 309 | 0.120 |
Why?
| | Estrogens | 1 | 2019 | 364 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6073 | 0.120 |
Why?
| | Prevalence | 2 | 2021 | 2861 | 0.110 |
Why?
| | Social Support | 1 | 2020 | 646 | 0.110 |
Why?
| | Societies, Medical | 1 | 2020 | 907 | 0.110 |
Why?
| | Milk Proteins | 2 | 2006 | 33 | 0.110 |
Why?
| | Schools | 1 | 2018 | 436 | 0.110 |
Why?
| | Leptin | 1 | 2017 | 248 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2019 | 536 | 0.110 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1036 | 0.110 |
Why?
| | Metabolome | 1 | 2019 | 390 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.110 |
Why?
| | Life Style | 2 | 2018 | 496 | 0.110 |
Why?
| | Pulse Wave Analysis | 3 | 2021 | 268 | 0.100 |
Why?
| | Phosphorus | 1 | 2014 | 89 | 0.100 |
Why?
| | Biopsy | 2 | 2008 | 1075 | 0.100 |
Why?
| | Asthma | 1 | 2006 | 1800 | 0.100 |
Why?
| | Inflammation Mediators | 1 | 2017 | 508 | 0.100 |
Why?
| | Glomerular Filtration Rate | 4 | 2020 | 745 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2006 | 2363 | 0.100 |
Why?
| | Signal Transduction | 2 | 2026 | 5246 | 0.090 |
Why?
| | Metabolomics | 1 | 2019 | 738 | 0.090 |
Why?
| | Exercise Therapy | 1 | 2018 | 488 | 0.090 |
Why?
| | Echocardiography | 1 | 2016 | 645 | 0.090 |
Why?
| | Blood Pressure | 2 | 2017 | 1765 | 0.090 |
Why?
| | Risk Assessment | 2 | 2017 | 3712 | 0.090 |
Why?
| | Ventricular Function, Left | 1 | 2016 | 541 | 0.090 |
Why?
| | Area Under Curve | 3 | 2008 | 335 | 0.090 |
Why?
| | Models, Theoretical | 1 | 2015 | 561 | 0.090 |
Why?
| | Regression Analysis | 2 | 2025 | 999 | 0.090 |
Why?
| | Models, Biological | 1 | 2019 | 1761 | 0.090 |
Why?
| | Pyruvic Acid | 2 | 2010 | 51 | 0.090 |
Why?
| | Fetal Growth Retardation | 1 | 2017 | 592 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.090 |
Why?
| | Emotions | 1 | 2017 | 559 | 0.090 |
Why?
| | Physicians | 1 | 2020 | 955 | 0.080 |
Why?
| | Hypoglycemia | 1 | 2016 | 490 | 0.080 |
Why?
| | Hypertension | 1 | 2019 | 1272 | 0.080 |
Why?
| | Creatinine | 3 | 2020 | 511 | 0.080 |
Why?
| | Disease Progression | 2 | 2022 | 2867 | 0.080 |
Why?
| | Genotype | 2 | 2025 | 1879 | 0.080 |
Why?
| | Treatment Outcome | 6 | 2019 | 11821 | 0.080 |
Why?
| | Diglycerides | 2 | 2026 | 66 | 0.070 |
Why?
| | Jet Lag Syndrome | 1 | 2019 | 13 | 0.070 |
Why?
| | Acyl Coenzyme A | 2 | 2006 | 32 | 0.070 |
Why?
| | Cohort Effect | 1 | 2009 | 5 | 0.070 |
Why?
| | Internship and Residency | 1 | 2020 | 1281 | 0.070 |
Why?
| | Asbestos | 1 | 2009 | 35 | 0.070 |
Why?
| | Protein Kinase C beta | 1 | 2008 | 21 | 0.070 |
Why?
| | Palmitates | 1 | 2008 | 21 | 0.070 |
Why?
| | Hypertriglyceridemia | 1 | 2008 | 45 | 0.070 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2005 | 175 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2025 | 1998 | 0.070 |
Why?
| | Age Distribution | 1 | 2009 | 399 | 0.070 |
Why?
| | Sex Distribution | 1 | 2009 | 382 | 0.070 |
Why?
| | Muscle Cells | 1 | 2007 | 41 | 0.060 |
Why?
| | Acetates | 1 | 2007 | 78 | 0.060 |
Why?
| | Quality Improvement | 1 | 2016 | 1354 | 0.060 |
Why?
| | Albuminuria | 2 | 2020 | 190 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2005 | 588 | 0.060 |
Why?
| | Trauma Severity Indices | 1 | 2007 | 115 | 0.060 |
Why?
| | Pregnancy | 4 | 2025 | 7230 | 0.060 |
Why?
| | Peptide YY | 1 | 2026 | 28 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2024 | 3017 | 0.060 |
Why?
| | Phenylalanine | 4 | 2009 | 69 | 0.060 |
Why?
| | Islets of Langerhans | 1 | 2012 | 852 | 0.060 |
Why?
| | Apolipoprotein B-100 | 1 | 2025 | 13 | 0.060 |
Why?
| | Carbon Dioxide | 1 | 2007 | 228 | 0.060 |
Why?
| | Muscular Atrophy | 1 | 2006 | 88 | 0.060 |
Why?
| | Milk | 1 | 2006 | 117 | 0.060 |
Why?
| | Animals | 8 | 2017 | 38107 | 0.050 |
Why?
| | Accelerometry | 1 | 2026 | 124 | 0.050 |
Why?
| | Caseins | 1 | 2004 | 20 | 0.050 |
Why?
| | Reference Values | 1 | 2026 | 796 | 0.050 |
Why?
| | Oxidation-Reduction | 1 | 2008 | 1075 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2026 | 150 | 0.050 |
Why?
| | Cystatin C | 2 | 2014 | 65 | 0.050 |
Why?
| | Self Report | 1 | 2019 | 870 | 0.050 |
Why?
| | Albumins | 1 | 2005 | 120 | 0.050 |
Why?
| | Endoplasmic Reticulum | 1 | 2026 | 268 | 0.050 |
Why?
| | Critical Care | 1 | 2010 | 706 | 0.050 |
Why?
| | Physical Exertion | 1 | 2005 | 204 | 0.050 |
Why?
| | Fibrinogen | 1 | 2005 | 182 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2026 | 615 | 0.050 |
Why?
| | Placebos | 2 | 2019 | 192 | 0.050 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 94 | 0.050 |
Why?
| | Stress, Physiological | 1 | 2006 | 450 | 0.050 |
Why?
| | Dietary Carbohydrates | 1 | 2003 | 146 | 0.050 |
Why?
| | Exercise Test | 3 | 2016 | 637 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2025 | 612 | 0.050 |
Why?
| | Glycolysis | 1 | 2024 | 342 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2022 | 112 | 0.040 |
Why?
| | Light | 1 | 2025 | 401 | 0.040 |
Why?
| | Critical Illness | 1 | 2007 | 908 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2006 | 628 | 0.040 |
Why?
| | Hydroxyestrones | 1 | 2000 | 2 | 0.040 |
Why?
| | Gonadotropins | 1 | 2020 | 44 | 0.040 |
Why?
| | Isoflavones | 1 | 2000 | 25 | 0.040 |
Why?
| | Chromosomes, Human, X | 1 | 2020 | 76 | 0.040 |
Why?
| | Anti-Mullerian Hormone | 1 | 2020 | 62 | 0.040 |
Why?
| | Sex Chromosome Aberrations | 1 | 2020 | 67 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2020 | 57 | 0.040 |
Why?
| | Registries | 1 | 2009 | 2400 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1888 | 0.040 |
Why?
| | Parental Leave | 1 | 2020 | 27 | 0.040 |
Why?
| | Trisomy | 1 | 2020 | 79 | 0.040 |
Why?
| | Causality | 1 | 2019 | 128 | 0.040 |
Why?
| | Hormones | 1 | 2019 | 134 | 0.040 |
Why?
| | Sulfonylurea Compounds | 1 | 2019 | 49 | 0.040 |
Why?
| | Administration, Oral | 3 | 2006 | 872 | 0.040 |
Why?
| | Rats, Zucker | 2 | 2010 | 32 | 0.040 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1591 | 0.040 |
Why?
| | Anxiety | 1 | 2025 | 1125 | 0.030 |
Why?
| | Biological Transport | 2 | 2010 | 424 | 0.030 |
Why?
| | Diabetic Angiopathies | 1 | 2019 | 265 | 0.030 |
Why?
| | Magnetic Resonance Angiography | 1 | 2018 | 249 | 0.030 |
Why?
| | Physicians, Primary Care | 1 | 2018 | 210 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2009 | 8391 | 0.030 |
Why?
| | Whey Proteins | 2 | 2006 | 9 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2016 | 117 | 0.030 |
Why?
| | Depression | 1 | 2025 | 1575 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 196 | 0.030 |
Why?
| | Sheep | 1 | 2017 | 870 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2020 | 6460 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1665 | 0.030 |
Why?
| | Rabbits | 2 | 2005 | 651 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1503 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2021 | 1369 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 497 | 0.020 |
Why?
| | Infant | 2 | 2019 | 10114 | 0.020 |
Why?
| | Mothers | 1 | 2020 | 772 | 0.020 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 146 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 199 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 363 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 874 | 0.020 |
Why?
| | Diet | 1 | 2000 | 1273 | 0.020 |
Why?
| | Glucagon | 1 | 2012 | 114 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1543 | 0.020 |
Why?
| | Parents | 1 | 2020 | 1394 | 0.020 |
Why?
| | Malonyl Coenzyme A | 1 | 2010 | 5 | 0.020 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2010 | 32 | 0.020 |
Why?
| | Glycogen | 1 | 2010 | 55 | 0.020 |
Why?
| | Sciatic Nerve | 1 | 2010 | 63 | 0.020 |
Why?
| | Rats | 2 | 2010 | 5586 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 568 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 432 | 0.020 |
Why?
| | Cholesterol, VLDL | 1 | 2008 | 5 | 0.020 |
Why?
| | Lactic Acid | 1 | 2010 | 295 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2010 | 282 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 846 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 790 | 0.020 |
Why?
| | Radioactive Tracers | 1 | 2007 | 5 | 0.020 |
Why?
| | Primary Health Care | 1 | 2018 | 1776 | 0.020 |
Why?
| | Citric Acid Cycle | 1 | 2007 | 58 | 0.020 |
Why?
| | Breath Tests | 1 | 2007 | 77 | 0.020 |
Why?
| | Sodium Bicarbonate | 1 | 2007 | 48 | 0.020 |
Why?
| | Cholesterol | 1 | 2008 | 411 | 0.020 |
Why?
| | Multienzyme Complexes | 1 | 2006 | 65 | 0.020 |
Why?
| | Palmitoylcarnitine | 1 | 2005 | 1 | 0.010 |
Why?
| | Methods | 1 | 2005 | 68 | 0.010 |
Why?
| | Carbohydrate Sequence | 1 | 2005 | 29 | 0.010 |
Why?
| | Palmitic Acid | 1 | 2005 | 40 | 0.010 |
Why?
| | Reference Standards | 1 | 2005 | 176 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2006 | 288 | 0.010 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2006 | 193 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 2005 | 115 | 0.010 |
Why?
| | Weight Lifting | 1 | 2004 | 33 | 0.010 |
Why?
| | Dietary Supplements | 1 | 2008 | 587 | 0.010 |
Why?
| | Hydrocortisone | 1 | 2006 | 303 | 0.010 |
Why?
| | Leucine | 1 | 2004 | 116 | 0.010 |
Why?
| | Fluorocarbons | 1 | 2005 | 122 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3206 | 0.010 |
Why?
| | Chromatography, Liquid | 1 | 2005 | 453 | 0.010 |
Why?
| | Patient Discharge | 1 | 2010 | 997 | 0.010 |
Why?
| | Heart Rate | 1 | 2007 | 846 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2006 | 1298 | 0.010 |
Why?
| | Blood Proteins | 1 | 2005 | 239 | 0.010 |
Why?
| | Phosphorylation | 1 | 2006 | 1724 | 0.010 |
Why?
| | Motor Activity | 1 | 2006 | 704 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2005 | 2092 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2838 | 0.010 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2000 | 33 | 0.010 |
Why?
| | Premenopause | 1 | 2000 | 130 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2005 | 2599 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2000 | 2418 | 0.000 |
Why?
|
|
Cree's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|